Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer

Mao, Li-jun; Ding, Meng; Xu, Kai; Pan, Jun; Yu, Haiyuan; Yang, Chunhua

doi:10.7150/jca.26437

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(23):4391-4397. doi:10.7150/jca.26437 This issue Cite

Research Paper

Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer

Li-jun Mao^1*, Meng Ding^1*, Kai Xu^1*, Jun Pan¹, Haiyuan Yu¹, Chunhua Yang^1,2✉

1. Department of Urinary Surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
2. Radiotherapy Department, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, China.
*Equal contributors.

Citation:

Mao Lj, Ding M, Xu K, Pan J, Yu H, Yang C. Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer. J Cancer 2018; 9(23):4391-4397. doi:10.7150/jca.26437. https://www.jcancer.org/v09p4391.htm

Other styles

Abstract

Purpose: Oncolytic adenoviruses emerge as new agents for cancer therapy. This study aimed to investigate the synergistic anti-tumor activity of oncolytic adenovirus armed with IL-24 (ZD55-IL-24) and docetaxel (DTX) on advanced prostate cancer in vitro and in vivo.

Methods: DU145 prostate cancer cells or nude mice xenografted with DU145 prostate cancer cells were treated by ZD55-IL-24 and DTX alone or in combination.

Results: DTX did not affect ZD55-IL-24 replication and IL-24 expression in DU145 cells. In vitro, the combination of ZD55-IL-24 and DTX showed synergistic inhibitory effects on prostate cancer cell viability and invasion. In vivo, ZD55-IL-24 and DTX synergistically inhibited the growth and activated the apoptosis of DU145 xenografts, accompanied by significantly decreased PARP-1 levels and increased caspase-3 and caspase-8 levels as well as decreased CD31 expression.

Conclusion: We reported the synergistic anti-tumor efficacy of ZD55-IL-24 and DTX on prostate cancer. Our results suggest that chemotherapy combined with oncolytic adenovirus mediated gene therapy is a promising strategy for the treatment of advanced prostate cancer.

Keywords: docetaxel, prostate cancer, IL-24, Oncolytic adenovirus

Citation styles

APA

Mao, L.j., Ding, M., Xu, K., Pan, J., Yu, H., Yang, C. (2018). Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer. Journal of Cancer, 9(23), 4391-4397. https://doi.org/10.7150/jca.26437.

ACS

Mao, L.j.; Ding, M.; Xu, K.; Pan, J.; Yu, H.; Yang, C. Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer. J. Cancer 2018, 9 (23), 4391-4397. DOI: 10.7150/jca.26437.

NLM

CSE

Mao Lj, Ding M, Xu K, Pan J, Yu H, Yang C. 2018. Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer. J Cancer. 9(23):4391-4397.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.